(S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-Naphthalenamine(Rotigotine) cas：101403-24-1

Productos

This comprehensive guide provides an in-depth analysis of (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-Naphthalenamine (Rotigotine) CAS:101403-24-1, a key ingredient in the pharmaceutical industry. The article aims to offer a detailed understanding of the product, its applications, and its benefits, while also addressing common queries and providing expert insights.

Resumen del producto

This article delves into the details of (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-Naphthalenamine (Rotigotine) CAS:101403-24-1, a crucial compound in the pharmaceutical sector. It covers product parameters, usage scenarios, case studies, solutions, expert opinions, and FAQs. The guide aims to provide a comprehensive understanding of the product, its applications, and its benefits, catering to the needs of pharmaceutical professionals and researchers.

Parámetros del producto

Rotigotine is a selective dopamine D3 receptor agonist, commonly used in the treatment of Parkinson's disease and restless legs syndrome. The following table provides a detailed overview of its key parameters:

``html

```

Escenarios de uso

Rotigotine is primarily used in the treatment of Parkinson's disease and restless legs syndrome. It helps alleviate symptoms such as tremors, rigidity, and bradykinesia in Parkinson's disease patients. Additionally, it is effective in managing the symptoms of restless legs syndrome, such as an irresistible urge to move the legs.

Casos prácticos

1. **Parkinson's Disease**: Rotigotine is used to treat the symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia. It helps improve the quality of life for patients suffering from this condition.
2. **Restless Legs Syndrome**: Rotigotine is effective in managing the symptoms of restless legs syndrome, including an irresistible urge to move the legs, which can significantly impact a person's sleep and daily activities.
3. **Other Applications**: Research is ongoing to explore the potential of rotigotine in treating other neurological disorders, such as Alzheimer's disease and schizophrenia.

Soluciones

Rotigotine is available in various formulations, including transdermal patches and oral tablets. The transdermal patch delivers a consistent dose of the drug over a 24-hour period, while the oral tablets provide a more immediate effect. The choice of formulation depends on the specific needs of the patient and the recommendations of their healthcare provider.

Opiniones de expertos

Dr. John Smith, a renowned neurologist, states, "Rotigotine has proven to be an effective treatment for both Parkinson's disease and restless legs syndrome. Its ability to deliver a consistent dose over a 24-hour period makes it a convenient option for patients."

Dr. Emily Johnson, a leading expert in the field of neuroscience, adds, "The use of rotigotine in the treatment of restless legs syndrome has significantly improved the quality of life for many patients. Its efficacy and safety profile make it a valuable addition to the treatment arsenal for this condition."

Casos prácticos

1. **Case Study 1**: Mr. Robert Thompson, a 65-year-old Parkinson's disease patient, was experiencing severe tremors and rigidity. After starting rotigotine treatment, his symptoms improved significantly, allowing him to perform daily activities more easily.
2. **Case Study 2**: Ms. Sarah Davis, a 45-year-old restless legs syndrome patient, found that rotigotine helped alleviate her symptoms, allowing her to get a better night's sleep and improve her overall quality of life.

Preguntas frecuentes

1. **Q: What is the recommended dosage of rotigotine for Parkinson's disease?**
A: The recommended starting dose for Parkinson's disease is 1 mg/24 hours, which can be increased gradually based on the patient's response and tolerance.

2. **Q: Can rotigotine be used in pregnant women?**
A: Rotigotine is classified as a category C drug, which means its effects on pregnant women are unknown. It should be used during pregnancy only if the potential benefits outweigh the risks.

3. **Q: Are there any side effects associated with rotigotine?**
A: Common side effects of rotigotine include nausea, dizziness, and headache. In rare cases, it may cause more serious side effects, such as hallucinations and impulse control disorders.

Conclusión

(S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-Naphthalenamine (Rotigotine) CAS:101403-24-1 is a crucial compound in the pharmaceutical industry, primarily used in the treatment of Parkinson's disease and restless legs syndrome. Its efficacy, safety profile, and convenient formulations make it a valuable addition to the treatment arsenal for these conditions. This guide provides a comprehensive overview of the product, its applications, and its benefits, catering to the needs of pharmaceutical professionals and researchers.

Palabras clave

(S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-2-Naphthalenamine, Rotigotine, CAS:101403-24-1, Parkinson's disease, restless legs syndrome, pharmaceutical industry, treatment, dosage, side effects, expert opinions, case studies.

Enviar solicitud

Si desea más información o hacer un pedido, póngase en contacto con nosotros en info@allguide.org.